Clinical Trial Update: A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Asenapine With Flexible Dosing From 5mg to 20mg in Adults With Developmental Stuttering [Phase 3]

View source ↗

Summary

This Phase 3 randomized, placebo-controlled trial evaluating asenapine (5–20 mg) for adults with developmental stuttering has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Developmental Stuttering

Drugs mentioned

• Asenapine (asenapine)

Snippet

Sponsor: University of California, Irvine | Conditions: Stuttering | Phase 3 | Status: SUSPENDED